Vyome Holdings, Inc. (NASDAQ:HIND) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Vyome Holdings, Inc. (NASDAQ:HIND) have earned a consensus rating of “Hold” from the five research firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $15.00.

HIND has been the topic of several research analyst reports. Zacks Research raised shares of Vyome to a “hold” rating in a research note on Wednesday, May 6th. Litchfield Hills Research initiated coverage on Vyome in a research note on Monday, May 4th. They issued a “buy” rating on the stock. Finally, Weiss Ratings upgraded Vyome from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday, May 1st.

Institutional Investors Weigh In On Vyome

A hedge fund recently bought a new stake in Vyome stock. Geode Capital Management LLC bought a new position in shares of Vyome Holdings, Inc. (NASDAQ:HIND) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 11,934 shares of the company’s stock, valued at approximately $41,000. Geode Capital Management LLC owned approximately 0.21% of Vyome at the end of the most recent quarter. Hedge funds and other institutional investors own 22.06% of the company’s stock.

Vyome Price Performance

Shares of NASDAQ:HIND opened at $2.18 on Wednesday. The business’s fifty day moving average price is $2.18 and its two-hundred day moving average price is $2.43. Vyome has a fifty-two week low of $1.75 and a fifty-two week high of $18.60. The stock has a market capitalization of $15.30 million, a price-to-earnings ratio of -0.18 and a beta of 1.49.

Vyome (NASDAQ:HIND) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.15) earnings per share (EPS) for the quarter. The business had revenue of $0.03 million during the quarter. Research analysts expect that Vyome will post -0.6 EPS for the current fiscal year.

About Vyome

ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.